难治复发B-ALL可以根据流式抗原表达考虑CD19 CAR-T细胞(Inaticabtagene Autoleucel,纳基奥仑赛)[43]、CD22抗体偶联药物[44]或CD19/CD3双特异性抗体[45]为基础的挽救治疗。. Here, CD22 is linked to acute lymphoblastic leukemia.